Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
1901 | 2436 | 40.1 | 74% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
230 | 3 | P GLYCOPROTEIN//FMO3//TRIMETHYLAMINURIA | 49374 |
1155 | 2 | PEPT1//ORGANIC CATION TRANSPORTER//OATP1B1 | 9490 |
1901 | 1 | BIOPHARMACEUTICS CLASSIFICATION SYSTEM//ORAL ABSORPTION//CACO 2 | 2436 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | BIOPHARMACEUTICS CLASSIFICATION SYSTEM | authKW | 592189 | 3% | 71% | 67 |
2 | ORAL ABSORPTION | authKW | 434036 | 5% | 28% | 125 |
3 | CACO 2 | authKW | 405653 | 8% | 16% | 206 |
4 | DRUG ABSORPTION | authKW | 318728 | 3% | 30% | 85 |
5 | BIORELEVANT MEDIA | authKW | 303804 | 2% | 61% | 40 |
6 | BIOWAIVER | authKW | 286440 | 2% | 57% | 40 |
7 | BIOPHARMACEUTICS CLASSIFICATION SYSTEM BCS | authKW | 243671 | 1% | 56% | 35 |
8 | PAMPA | authKW | 241068 | 2% | 36% | 53 |
9 | HUMAN INTESTINAL FLUID | authKW | 213723 | 1% | 95% | 18 |
10 | INTESTINAL ABSORPTION | authKW | 201869 | 6% | 11% | 143 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 53184 | 84% | 0% | 2046 |
2 | Chemistry, Medicinal | 8623 | 18% | 0% | 440 |
3 | Chemistry, Multidisciplinary | 3715 | 27% | 0% | 655 |
4 | Medicine, Research & Experimental | 403 | 6% | 0% | 145 |
5 | Toxicology | 230 | 4% | 0% | 90 |
6 | Computer Science, Interdisciplinary Applications | 60 | 2% | 0% | 49 |
7 | Integrative & Complementary Medicine | 25 | 1% | 0% | 13 |
8 | Mathematical & Computational Biology | 24 | 1% | 0% | 22 |
9 | Biochemical Research Methods | 15 | 2% | 0% | 45 |
10 | Chemistry, Analytical | 7 | 2% | 0% | 58 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | BIOPHARMACEUT PHARMACEUT SCI CLIN SUPPLY | 83548 | 0% | 67% | 10 |
2 | BIOPHARMACEUT PHARMACOKINET | 78196 | 2% | 11% | 56 |
3 | GRP BIOPHARMACEUT | 50133 | 0% | 100% | 4 |
4 | BIOPHARMACEUT GRP | 48192 | 0% | 38% | 10 |
5 | THER EUT EQUIVALENCE | 44759 | 0% | 71% | 5 |
6 | AREA PHARM PHARMACEUT TECHNOL | 39163 | 0% | 63% | 5 |
7 | COMPETENCE SYST BIOL COMPUTAT SOLUT | 39163 | 0% | 63% | 5 |
8 | PHARMACOTECHNOL BIOPHARM | 38507 | 1% | 13% | 23 |
9 | PHARMACOKINET PHARMACEUT TECHNOL | 37600 | 0% | 100% | 3 |
10 | FORMULAT | 31531 | 1% | 11% | 23 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PHARMACEUTICAL RESEARCH | 122102 | 11% | 4% | 279 |
2 | EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES | 114135 | 7% | 5% | 179 |
3 | DISSOLUTION TECHNOLOGIES | 107780 | 2% | 20% | 42 |
4 | JOURNAL OF PHARMACEUTICAL SCIENCES | 67659 | 10% | 2% | 246 |
5 | MOLECULAR PHARMACEUTICS | 58188 | 5% | 4% | 121 |
6 | AAPS JOURNAL | 46739 | 3% | 6% | 65 |
7 | INTERNATIONAL JOURNAL OF PHARMACEUTICS | 21652 | 7% | 1% | 166 |
8 | EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS | 20479 | 3% | 2% | 78 |
9 | DRUG METABOLISM AND DISPOSITION | 7852 | 3% | 1% | 69 |
10 | BIOPHARMACEUTICS & DRUG DISPOSITION | 7468 | 1% | 2% | 34 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | BIOPHARMACEUTICS CLASSIFICATION SYSTEM | 592189 | 3% | 71% | 67 | Search BIOPHARMACEUTICS+CLASSIFICATION+SYSTEM | Search BIOPHARMACEUTICS+CLASSIFICATION+SYSTEM |
2 | ORAL ABSORPTION | 434036 | 5% | 28% | 125 | Search ORAL+ABSORPTION | Search ORAL+ABSORPTION |
3 | CACO 2 | 405653 | 8% | 16% | 206 | Search CACO+2 | Search CACO+2 |
4 | DRUG ABSORPTION | 318728 | 3% | 30% | 85 | Search DRUG+ABSORPTION | Search DRUG+ABSORPTION |
5 | BIORELEVANT MEDIA | 303804 | 2% | 61% | 40 | Search BIORELEVANT+MEDIA | Search BIORELEVANT+MEDIA |
6 | BIOWAIVER | 286440 | 2% | 57% | 40 | Search BIOWAIVER | Search BIOWAIVER |
7 | BIOPHARMACEUTICS CLASSIFICATION SYSTEM BCS | 243671 | 1% | 56% | 35 | Search BIOPHARMACEUTICS+CLASSIFICATION+SYSTEM+BCS | Search BIOPHARMACEUTICS+CLASSIFICATION+SYSTEM+BCS |
8 | PAMPA | 241068 | 2% | 36% | 53 | Search PAMPA | Search PAMPA |
9 | HUMAN INTESTINAL FLUID | 213723 | 1% | 95% | 18 | Search HUMAN+INTESTINAL+FLUID | Search HUMAN+INTESTINAL+FLUID |
10 | INTESTINAL ABSORPTION | 201869 | 6% | 11% | 143 | Search INTESTINAL+ABSORPTION | Search INTESTINAL+ABSORPTION |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | BUCKLEY, ST , FISCHER, SM , FRICKER, G , BRANDL, M , (2012) IN VITRO MODELS TO EVALUATE THE PERMEABILITY OF POORLY SOLUBLE DRUG ENTITIES: CHALLENGES AND PERSPECTIVES.EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 45. ISSUE 3. P. 235-250 | 102 | 79% | 35 |
2 | LARREGIEU, CA , BENET, LZ , (2013) DRUG DISCOVERY AND REGULATORY CONSIDERATIONS FOR IMPROVING IN SILICO AND IN VITRO PREDICTIONS THAT USE CACO-2 AS A SURROGATE FOR HUMAN INTESTINAL PERMEABILITY MEASUREMENTS.AAPS JOURNAL. VOL. 15. ISSUE 2. P. 483-497 | 90 | 71% | 17 |
3 | SUGANO, K , (2009) INTRODUCTION TO COMPUTATIONAL ORAL ABSORPTION SIMULATION.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 5. ISSUE 3. P. 259-293 | 111 | 56% | 31 |
4 | LENNERNAS, H , (2014) REGIONAL INTESTINAL DRUG PERMEATION: BIOPHARMACEUTICS AND DRUG DEVELOPMENT.EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 57. ISSUE . P. 333 -341 | 62 | 83% | 15 |
5 | MACHERAS, P , KARALIS, V , VALSAMI, G , (2013) KEEPING A CRITICAL EYE ON THE SCIENCE AND THE REGULATION OF ORAL DRUG ABSORPTION: A REVIEW.JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 102. ISSUE 9. P. 3018-3036 | 91 | 61% | 6 |
6 | WU, CN , LIU, Y , HE, ZG , SUN, J , (2016) INSIGHT INTO THE DEVELOPMENT OF DISSOLUTION MEDIA FOR BCS CLASS II DRUGS: A REVIEW FROM QUALITY CONTROL AND PREDICTION OF IN VIVO PERFORMANCE PERSPECTIVES.CURRENT DRUG DELIVERY. VOL. 13. ISSUE 7. P. 1004 -1020 | 89 | 59% | 0 |
7 | AVDEEF, A , TAM, KY , (2010) HOW WELL CAN THE CACO-2/MADIN-DARBY CANINE KIDNEY MODELS PREDICT EFFECTIVE HUMAN JEJUNAL PERMEABILITY?.JOURNAL OF MEDICINAL CHEMISTRY. VOL. 53. ISSUE 9. P. 3566-3584 | 75 | 75% | 24 |
8 | LENNERNAS, H , (2014) HUMAN IN VIVO REGIONAL INTESTINAL PERMEABILITY: IMPORTANCE FOR PHARMACEUTICAL DRUG DEVELOPMENT.MOLECULAR PHARMACEUTICS. VOL. 11. ISSUE 1. P. 12-23 | 68 | 71% | 14 |
9 | KOSTEWICZ, ES , AARONS, L , BERGSTRAND, M , BOLGER, MB , GALETIN, A , HATLEY, O , JAMEI, M , LLOYD, R , PEPIN, X , ROSTAMI-HODJEGAN, A , ET AL (2014) PBPK MODELS FOR THE PREDICTION OF IN VIVO PERFORMANCE OF ORAL DOSAGE FORMS.EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 57. ISSUE . P. 300 -321 | 88 | 45% | 41 |
10 | DAHLGREN, D , ROOS, C , SJOREN, E , LENNERNA, H , (2015) DIRECT IN VIVO HUMAN INTESTINAL PERMEABILITY (P-EFF) DETERMINED WITH DIFFERENT CLINICAL PERFUSION AND INTUBATION METHODS.JOURNAL OF PHARMACEUTICAL SCIENCES. VOL. 104. ISSUE 9. P. 2702 -2726 | 86 | 55% | 4 |
Classes with closest relation at Level 1 |